Targeting the JAK/STAT Signaling Pathway for Breast Cancer

Title:Targeting the JAK/STAT Signaling Pathway for Breast Cancer

Volume: 28 Issue: 25

Author(s): Fei Shao, Xiaonan Pang and Gyeong Hun Baeg*

Affiliation:

• Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, Chinese University of Hong Kong, Shenzhen, Guangdong 518172,China

Keywords: Breast cancer, JAK/STAT pathway, inhibitors, targeted therapy, therapeutics, STAT3 dimerization.

Abstract: Breast cancer is the most common malignant tumor in women worldwide. Traditional ways of treatment, including radiotherapy and endocrine therapy, for breast cancer have inevitable side effects. In recent decades, targeted therapies for breast cancer have rapidly advanced and shown a promising future. The JAK/STAT signaling pathway has been shown to play important roles in tumorigenesis, maintenance and metastasis of breast cancer. Hence, many small molecule inhibitors of JAK and STAT proteins have been developed. These inhibitors exhibit potent inhibitory effects on breast cancer in both cellular and animal models, and even some of them have already been in clinical trials. This review article discussed the JAK/STAT signal transduction pathway in the pathogenesis of breast cancer, and the potential for the application of JAK/STAT inhibitors in breast cancer treatment.

Cite this article as:

Shao Fei , Pang Xiaonan and Baeg Hun Gyeong *, Targeting the JAK/STAT Signaling Pathway for Breast Cancer, Current Medicinal Chemistry 2021; 28 (25) . https://dx.doi.org/10.2174/0929867328666201207202012